Romonia Renee Reams
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Romonia Renee Reams has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Adriana C. Vidal
Department of Surgery, Center for Integrated Research on Cancer and Lifestyle, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
9 shared publications - Allison Reagan
Division of Urology, Veterans Affairs Health Care System, Durham VA Medical Center, Durham, North Carolina
9 shared publications - Emily Wiggins
Division of Urology, Veterans Affairs Health Care System, Durham VA Medical Center, Durham, North Carolina
9 shared publications - Hemal H. Mehta
Leonard Davis School of Gerontology, University of Southern California, Los Angeles, California
9 shared publications - Jessica L. Janes
Urology Section, Department of Surgery, Veterans Affairs Health Care System, Durham, USA
9 shared publications - Jiali Liu
Xi'an Jiaotong University Second Affiliated Hospital
9 shared publications
Latest Publications
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S3 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Figure S3 shows receiver operating characteristic (ROC) curves between univariable models adjusted for PSA (log-transformed) only, Plasma mtDNA only, and WBC mtDNA only, stratified by Black and White individuals.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S3 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Figure S3 shows receiver operating characteristic (ROC) curves between univariable models adjusted for PSA (log-transformed) only, Plasma mtDNA only, and WBC mtDNA only, stratified by Black and White individuals.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S1 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Figure S1 shows a comparison of control Mitochondrial DNA copy number levels by BPH status for Black and White individuals
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S1 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Figure S1 shows a comparison of control Mitochondrial DNA copy number levels by BPH status for Black and White individuals
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S2 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Figure S2 shows the comparison of control Mitochondrial DNA copy number levels in White and Black Individuals
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S2 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Figure S2 shows the comparison of control Mitochondrial DNA copy number levels in White and Black Individuals
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table S3 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Table S3 shows univariable and multivariable multinomial logistic regression models for testing the association between mtDNA copy number and prostate cancer grade stratified by race
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S3 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Table S3 shows univariable and multivariable multinomial logistic regression models for testing the association between mtDNA copy number and prostate cancer grade stratified by race
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S4 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Figure S4 shows a comparison of the distribution of Mitochondrial DNA copy number by prostate cancer grade for Black and White Individuals stratified by plasma and WBC.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S4 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Figure S4 shows a comparison of the distribution of Mitochondrial DNA copy number by prostate cancer grade for Black and White Individuals stratified by plasma and WBC.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Data from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Black individuals are disproportionately burdened by prostate cancer compared with White individuals. The mitochondrion is an untapped source for prostate cancer biomarkers, and previous work has shown that altered mitochondrial DNA (mtDNA) copy number is linked to mitochondrial dysfunction and tumorigenesis. We assess whether mtDNA copy number is altered in patients with and without prostate cancer in a racially specific manner. Circulating cell-free mtDNA copy number from plasma and mtDNA copy number from white blood cells (WBC) were measured in 199 patients undergoing biopsy (50:50 White cases/controls and 50:49 Black cases/controls). mtDNA copy number was determined via Droplet Digital PCR. Logistic regressions tested associations between mtDNA and prostate cancer by race. The AUC was compared between covariate-only models and models with mtDNA. In both plasma and WBCs, mtDNA copy number was significantly increased in cases compared with controls in White patients, but not in Black patients. Interestingly, Black controls had higher mtDNA copy number levels than White controls. Multivariable analysis revealed significant associations of plasma mtDNA and WBC mtDNA with prostate cancer for White patients only. Elevated mtDNA copy number was more accurate in predicting prostate cancer in White patients than in Black patients. Higher mtDNA copy number levels were associated with prostate cancer in both Black and White patients. Plasma mtDNA may be more accurate than WBC mtDNA in predicting prostate cancer incidence in Black men. Overall, Black controls had higher mtDNA copy number levels than White controls, suggesting mtDNA copy number may be implicated in prostate cancer health disparities.Prevention Relevance:Our study shows that mtDNA copy number is a significant predictor of prostate cancer in White individuals, suggesting its potential use in early detection and prevention strategies. The absence of this association in Black individuals highlights the need for race-specific biomarkers in prostate cancer prevention efforts.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Black individuals are disproportionately burdened by prostate cancer compared with White individuals. The mitochondrion is an untapped source for prostate cancer biomarkers, and previous work has shown that altered mitochondrial DNA (mtDNA) copy number is linked to mitochondrial dysfunction and tumorigenesis. We assess whether mtDNA copy number is altered in patients with and without prostate cancer in a racially specific manner. Circulating cell-free mtDNA copy number from plasma and mtDNA copy number from white blood cells (WBC) were measured in 199 patients undergoing biopsy (50:50 White cases/controls and 50:49 Black cases/controls). mtDNA copy number was determined via Droplet Digital PCR. Logistic regressions tested associations between mtDNA and prostate cancer by race. The AUC was compared between covariate-only models and models with mtDNA. In both plasma and WBCs, mtDNA copy number was significantly increased in cases compared with controls in White patients, but not in Black patients. Interestingly, Black controls had higher mtDNA copy number levels than White controls. Multivariable analysis revealed significant associations of plasma mtDNA and WBC mtDNA with prostate cancer for White patients only. Elevated mtDNA copy number was more accurate in predicting prostate cancer in White patients than in Black patients. Higher mtDNA copy number levels were associated with prostate cancer in both Black and White patients. Plasma mtDNA may be more accurate than WBC mtDNA in predicting prostate cancer incidence in Black men. Overall, Black controls had higher mtDNA copy number levels than White controls, suggesting mtDNA copy number may be implicated in prostate cancer health disparities.Prevention Relevance:Our study shows that mtDNA copy number is a significant predictor of prostate cancer in White individuals, suggesting its potential use in early detection and prevention strategies. The absence of this association in Black individuals highlights the need for race-specific biomarkers in prostate cancer prevention efforts.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Table S1 contains mtDNA copy numbers used in this study for Black and White individuals.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Table S1 contains mtDNA copy numbers used in this study for Black and White individuals.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table S2 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Table S2 shows demographic and clinical characteristics at the time of biopsy stratified by prostate cancer grade for all individuals and by race.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S2 from Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Supplemental Table S2 shows demographic and clinical characteristics at the time of biopsy stratified by prostate cancer grade for all individuals and by race.
- Open Access
- 26 June 2025
- Published by Springer Nature in Journal of Cancer Education
- Vol. 41 (3) , 426-434
Training the Next Generation of Researchers to Advance Cancer Health Equity: Five Years of Experience from the Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
The underrepresentation of racial and ethnic minority scientists in research is a significant barrier to eliminating cancer health disparities. There is a compelling need to develop a cadre of racially and ethnically diverse, well-trained scientists to effectively meet the nation’s biomedical, behavioral, population, and clinical cancer research needs. The Florida-California Cancer Research, Education and Engagement Health Equity Center’s program focuses on training this underrepresented workforce. Our center is a tri-institutional collaboration between Florida A&M University, University of Florida, and University of Southern California. Here, we report the organizational structure and initial outcomes of our program to support 130 unique talented, underrepresented individuals in 138 cancer research training positions. Over the past 5 years, we offered the following: (1) a 12-week early and focused exposure of 35 undergraduate students; (2) training and support of 23 postbaccalaureate trainees in a 1-year mentored research and training program; and (3) academic career development, mentorship, and tailored research training opportunities to increase the competitive research capacity for 33 graduate students, 13 post-doctoral scholars, and 34 early-stage investigators. Educators, researchers, policymakers, and community leaders can use our training models to advance equity through excellence in education and research for underrepresented minority populations, ultimately fostering a more just and inclusive society.
- 26 June 2025
- Published by Springer Nature in Journal of Cancer Education
- Vol. 41 (3) , 426-434
Open AccessTraining the Next Generation of Researchers to Advance Cancer Health Equity: Five Years of Experience from the Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
The underrepresentation of racial and ethnic minority scientists in research is a significant barrier to eliminating cancer health disparities. There is a compelling need to develop a cadre of racially and ethnically diverse, well-trained scientists to effectively meet the nation’s biomedical, behavioral, population, and clinical cancer research needs. The Florida-California Cancer Research, Education and Engagement Health Equity Center’s program focuses on training this underrepresented workforce. Our center is a tri-institutional collaboration between Florida A&M University, University of Florida, and University of Southern California. Here, we report the organizational structure and initial outcomes of our program to support 130 unique talented, underrepresented individuals in 138 cancer research training positions. Over the past 5 years, we offered the following: (1) a 12-week early and focused exposure of 35 undergraduate students; (2) training and support of 23 postbaccalaureate trainees in a 1-year mentored research and training program; and (3) academic career development, mentorship, and tailored research training opportunities to increase the competitive research capacity for 33 graduate students, 13 post-doctoral scholars, and 34 early-stage investigators. Educators, researchers, policymakers, and community leaders can use our training models to advance equity through excellence in education and research for underrepresented minority populations, ultimately fostering a more just and inclusive society.
- 13 May 2025
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 18 (9) , 541-550
Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Black individuals are disproportionately burdened by prostate cancer compared with White individuals. The mitochondrion is an untapped source for prostate cancer biomarkers, and previous work has shown that altered mitochondrial DNA (mtDNA) copy number is linked to mitochondrial dysfunction and tumorigenesis. We assess whether mtDNA copy number is altered in patients with and without prostate cancer in a racially specific manner. Circulating cell-free mtDNA copy number from plasma and mtDNA copy number from white blood cells (WBC) were measured in 199 patients undergoing biopsy (50:50 White cases/controls and 50:49 Black cases/controls). mtDNA copy number was determined via Droplet Digital PCR. Logistic regressions tested associations between mtDNA and prostate cancer by race. The AUC was compared between covariate-only models and models with mtDNA. In both plasma and WBCs, mtDNA copy number was significantly increased in cases compared with controls in White patients, but not in Black patients. Interestingly, Black controls had higher mtDNA copy number levels than White controls. Multivariable analysis revealed significant associations of plasma mtDNA and WBC mtDNA with prostate cancer for White patients only. Elevated mtDNA copy number was more accurate in predicting prostate cancer in White patients than in Black patients. Higher mtDNA copy number levels were associated with prostate cancer in both Black and White patients. Plasma mtDNA may be more accurate than WBC mtDNA in predicting prostate cancer incidence in Black men. Overall, Black controls had higher mtDNA copy number levels than White controls, suggesting mtDNA copy number may be implicated in prostate cancer health disparities. Prevention Relevance: Our study shows that mtDNA copy number is a significant predictor of prostate cancer in White individuals, suggesting its potential use in early detection and prevention strategies. The absence of this association in Black individuals highlights the need for race-specific biomarkers in prostate cancer prevention efforts.
- 13 May 2025
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 18 (9) , 541-550
Mitochondrial DNA Copy-Number Assessment Is a Potent Predictor for Prostate Cancer in White but Not Black Individuals
Black individuals are disproportionately burdened by prostate cancer compared with White individuals. The mitochondrion is an untapped source for prostate cancer biomarkers, and previous work has shown that altered mitochondrial DNA (mtDNA) copy number is linked to mitochondrial dysfunction and tumorigenesis. We assess whether mtDNA copy number is altered in patients with and without prostate cancer in a racially specific manner. Circulating cell-free mtDNA copy number from plasma and mtDNA copy number from white blood cells (WBC) were measured in 199 patients undergoing biopsy (50:50 White cases/controls and 50:49 Black cases/controls). mtDNA copy number was determined via Droplet Digital PCR. Logistic regressions tested associations between mtDNA and prostate cancer by race. The AUC was compared between covariate-only models and models with mtDNA. In both plasma and WBCs, mtDNA copy number was significantly increased in cases compared with controls in White patients, but not in Black patients. Interestingly, Black controls had higher mtDNA copy number levels than White controls. Multivariable analysis revealed significant associations of plasma mtDNA and WBC mtDNA with prostate cancer for White patients only. Elevated mtDNA copy number was more accurate in predicting prostate cancer in White patients than in Black patients. Higher mtDNA copy number levels were associated with prostate cancer in both Black and White patients. Plasma mtDNA may be more accurate than WBC mtDNA in predicting prostate cancer incidence in Black men. Overall, Black controls had higher mtDNA copy number levels than White controls, suggesting mtDNA copy number may be implicated in prostate cancer health disparities. Prevention Relevance: Our study shows that mtDNA copy number is a significant predictor of prostate cancer in White individuals, suggesting its potential use in early detection and prevention strategies. The absence of this association in Black individuals highlights the need for race-specific biomarkers in prostate cancer prevention efforts.